Member Info for DaProphet

Just asked AI and it says otherwise..

Apparently the old cashburn rate i worked out from the intrims was too high because they were paying off old liabilities. So it's just admin now at a much lower rate ..

Approximately 15–18 months from now (mid-2027) before cash depletion on the current run-rate, but a raise will likely be needed sooner if/when a reverse takeover target is pursued.Breaking it down based on the latest reported data (unaudited interims to 30 September 2025, published 30 December 2025):Cash balance at 30 Sep 2025: £599,702

3.3 months have passed since then (to 9 Jan 2026), so estimated cash burned in that period: **£105,000** (at ongoing rate – see below)

Estimated current cash: ~£495,000

Ongoing monthly cash burn proxy:Recurring administrative expenses were £189,247 over the 6-month period → ~£31,500–£32,000 per month

This is considered the best forward run-rate now that the balance sheet clean-up (one-off liability settlements that inflated the reported £65k/month average) is largely complete.

Management describes future G&A outflows as “expected to be modest”, consistent with this lower level.

Runway calculation:£495,000 ÷ £32,000/month ≈ 15.5 months from now.

Gives a buffer into mid-2027 assuming no material increase in spending.

Important caveats from the company itself:Current cash is “considered sufficient to cover the Company's near-term due diligence requirements on potential acquisition targets.”

Worse comes to worse i think we are definitely safe for another 6 months

They've got about up to 3 months imo to sort a deal otherwise a further placing will be needed.

I think Cashburn is about £60k a month

Surely it would be a small placing anyhow if RTO is imminent 🤷

That's if we are desperate for funds to keep the lights on.. can imagine cashburn being extremely limited

Dodgy fecker..good riddance

The company claims this could reduce AI compute costs by 50–80% and improve "time to first answer" speeds by 5–10x what's not to like here..

We have two subnets working in two different environments

Who else does that?

Is financing the next catalyst due?

And is this supposedly Q1-Q2

How long has it been since the rumour started?

Any spies out there..👀👀

Are any of the Tr1's inconjunction to freedom .. anybody done any r&r on LinkedIn?

"Bixby is invisible. He has abandoned his Tiger cub."

Pretty sure he wrote the last Rns a couple of weeks ago.

Whilst his communication has been somewhat quiet i imagine he's just a very busy individual..this isn't his only job.

TAO as well as crypto is in a bear cycle at present these are the times to accumulate if you believe in the story .

I asked Gemini &grok if this was a better buy right now vs ASTR

And it pointed to #TIR being the suggested choice.

Analysis say after the next cycle 4+ years away Tao could be commanding an asking price of around $6000👀

"those TR1 holders can’t all be wrong'' well they can be, we have seen so many times tr1 holders get shafteed too"

In here?

Well I've noticed afew in the past did okay getting out on spikes so they surely knew about something happening 😜

Yup retail will be the last to know..

But you can bet your last dollar someone knows something that's been buying in recently

Everybody's talking about the bird!

Get in son!

And yet another stonking low ar@e scratching buying opportunity

Market seems happy..back up to the .02s or will the newbie's be taking their profits and flipping 🤔

And to add further clarification on those that aren't aware of this truly horrible stain on humanity..he/she works hand in hand under the Tom winneyfilth umbrella on these boards!

Utter nonsense !

Here's why...

AVA6000 (faridoxorubicin) is a prodrug designed for rapid clearance from circulation if not cleaved by FAP in the tumor microenvironment, minimizing systemic toxicity. Its plasma half-life is indeed short (~45 minutes based on early modeling), but this is a feature, not a flaw—it ensures uncleaved drug is quickly eliminated (e.g., via renal clearance), reducing off-target effects.

Once cleaved, the released doxorubicin has an extended plasma half-life of 35 hours (up ~40-45% compared to standard doxorubicin's ~24-30 hours), with reduced peak concentrations (Cmax down 40-50%) and peripheral distribution. This leads to **100-fold higher doxorubicin concentration in tumors vs. plasma** (tumor:plasma ratio of 100:1 in biopsies), confirming effective targeting and sustained exposure at the tumor site.

**No data supports the idea that most of the drug ends up ineffective in the bladder without reaching tumors. Instead, translational data from Phase 1a/1b shows efficient cleavage and dose-dependent intratumoral doxorubicin levels, even in tumors with low FAP expression (via bystander effect).

I'll have a word with the chef..cheese leak did you say?

If someone is viewing the data room and discussions are ongoing

There will be no case for loose lips

Great news but let's not get ahead of ourselves.

After all Resources are contingent (not yet reserves), requiring further appraisal, drilling, and commercial hurdles

Expect a nice 30% here today hopefully 🤞

Some great posts today so can't really add anything other than we are still well very undervalued..and no doubt when warrants are clear this will branch up to more sensible levels.

I have a Q1 target of around 8-10p

I Will be only trading a small pot the rest is allocated long term .. that's where the real money is made 💰💰

I'm 3 bags up so far and haven't sold a 🫘

You having fun carrot 🥕

Get a life ffs!

RICKSTER68

Yes warrants are dilution but they also add revenue

And are a necessity to attract investors ..

The warrants are usually sold asap for immediate profit yes ..they act as a sweetener and reduce the cost basis of the primary investment.

I take it you are new to small caps🤷..

Nothing wrong with asking the qustions just don't be so prejudice in your judgement